ClinicalTrials.gg
RecruitingNCT06439563Updated Nov 1, 2024

Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers

A Phase 3 interventional study of JP-1366 10 mg and Lanston Capsule 15 mg in Peptic Ulcer, sponsored by Onconic Therapeutics Inc.. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-11-01.

Sponsored by Onconic Therapeutics Inc. (part of Jeil Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
364
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Peptic Ulcer with a site in Korea, Republic of — 4 open to participants now, 5 under way, 3 of them phase 3. Peptic Ulcer · Korea, Republic of.

Planned enrollment
8th of 16
364 · median 344
Started
2024
with 1 other
Phase 3
7 of 19
2 open now
Registered
17th of 19
by date

Among the 19 studies in Peptic Ulcer with a site in Korea, Republic of, this one is the 8th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2024, is one of 7 in phase 3, and was the 17th registered.

Peptic Ulcer

146 studies on the registry are indexed under Peptic Ulcer; 25 are open to participants now.

Browse Peptic Ulcer studies →

Open to participants now

4 of the 19 studies in Peptic Ulcer with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 18 Peptic Ulcer studies recruiting now, 11 (61%) set no upper age limit and 7 (39%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Peptic Ulcer with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The sutdy aims to to demonstrate the non-inferiority of JP-1366 10 mg compared to Lanston Capsule 15 mg in preventing NSAIDs-induced peptic ulcers and to compare/evaluate the efficacy and safety of JP-1366 10 mg.

03

Conditions studied

  • Peptic Ulcer

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult male/female aged 19 years or older as of the date of obtaining consent
  2. Those who are diagnosed with musculoskeletal diseases such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, or other diseases at the time of screening and require continuous administration of NSAIDs for 24 weeks or more
  3. Those with one or more of the following risk factors for ulcer development at the time of screening
  4. Subjects who fully understand this study and voluntarily signed the form.

Exclusion criteria

Exclusion Criteria:

  1. Those who cannot undergo upper gastrointestinal endoscopy
  2. At the time of screening, those who were confirmed to have active stage ulcers (A1, A2) or healing stage ulcers (H1, H2) in the stomach or duodenum according to the Sakita-Miwa Classification*
  3. Those with a confirmed history of malignant tumor within 5 years
  4. Those with a confirmed history of signal symptoms suggestive of malignant disease of the gastrointestinal tract
  5. Those who need to continuously take , antiplatelet agents, and anticoagulants during this study (however, the following cases are permitted):
  6. Pregnant and lactating women or those with a positive pregnancy test result at screening
  7. Those who participated in another study and were administered products or had medical devices applied at least once within 4 weeks from the screening visit(Visit 0)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
364 participants (estimated)

Study arms

  • Experimental
    JP-1366 10 mg

    Drug: JP-1366 10 mg · Drug: Lanston Capsule 15 mg placebo

  • Active comparator
    Lanston Capsule 15 mg

    Drug: Lanston Capsule 15 mg · Drug: JP-1366 10 mg placebo

Interventions

  • JP-1366 10 mg, tablet, orally once a day for up to 24 weeks

  • DrugLanston Capsule 15 mg

    Lanston Capsule 15 mg orally once a day for up to 24 weeks

  • DrugJP-1366 10 mg placebo

    JP-1366 10 mg placebo, tablet, orally once a day for up to 24 weeks

  • DrugLanston Capsule 15 mg placebo

    Lanston Capsule 15 mg placebo, orally once a day for up to 24 weeks

06

What researchers measure

Primary outcomes

  1. Cumulative proportion of subjects who developed peptic ulcers

    Time frame: at 24 weeks after administration of investigational products

Secondary outcomes

  1. Proportion of subjects with gastric or duodenal endoscopic bleeding

    Time frame: at 24 weeks after administration of investigational products

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Aug 2027, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2024
First posted
Jun 3, 2024
StartActual
Oct 22, 2024
Primary completionEst.
Aug 2027
CompletionEst.
Dec 2027
Last update
Nov 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06439563
Responsible party
Sponsor
First posted
Jun 3, 2024
Start date
Oct 22, 2024
Primary completion
Aug 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 1, 2024

Study contacts

John KIM
Contact
onconictherapeutics@gmail.com
0234540780

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zastaprazan

Start the discussion